STOCK TITAN

Aptevo extends rights agreement to October 2027

The amendment sets the rights’ stated expiration date at October 23, 2027 and the Purchase Price at $14.56 per one one-thousandth of a Preferred Share.

(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. amended its Rights Agreement with Broadridge Corporate Issuer Solutions, LLC, as rights agent, on October 23, 2026. The amendment extends the defined “Final Expiration Date” to October 23, 2027, and changes the defined “Purchase Price” to $14.56 per one one-thousandth of a Series A Junior Participating Preferred Share, which has a par value of $0.001 per share.

Insights

Analyzing...

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Final Expiration Date October 23, 2027 Date in the amended definition
Purchase Price $14.56 per one one-thousandth of a Preferred Share Amended term under the Rights Agreement
Preferred Share par value $0.001 per share Series A Junior Participating Preferred Stock
Preferred Share fraction per right One one-thousandth of a share Contingent right to purchase Series A Junior Participating Preferred Stock
Rights Agreement regulatory
"Amendment No. 6 to the Rights Agreement"
A rights agreement is a contract that grants existing shareholders special rights—commonly the option to buy additional shares at a set price or to trigger protections if a takeover is attempted. Think of it like a neighborhood watch rule that lets current homeowners buy extra lots or lock the gate when an outsider tries to take over the block; it matters to investors because it can dilute or protect share value and influence takeover outcomes.
rights agent regulatory
"as rights agent"
A rights agent is a neutral third party, usually a bank or trust company, that runs the mechanical parts of a company’s rights offering — tracking who gets rights, processing requests to buy additional shares, collecting payments, and issuing the new stock. For investors, the rights agent ensures the offer is handled correctly and on time, which affects the ability to exercise rights and the perceived fairness and legality of the transaction.
Final Expiration Date regulatory
"definition of “Final Expiration Date”"
Purchase Price financial
"definition of “Purchase Price”"
The purchase price is the amount of money paid to acquire an asset—such as shares, a business, real estate, or equipment. It matters to investors because it sets the baseline for future profit, loss, taxes and accounting values; think of it like the price you pay for a used car, which determines your potential resale gain or loss. Investors compare purchase price to expected future cash flows and market values to judge whether an investment is a good deal.
Series A Junior Participating Preferred Stock financial
"Series A Junior Participating Preferred Stock"
A Series A junior participating preferred stock is a specific class of preferred share that gives its holders a priority payment when a company distributes cash (like dividends or sale proceeds) but ranks below any senior preferred shares for those payments; the “participating” feature lets holders also share in leftover proceeds with common shareholders after receiving their preference. For investors this means a mix of downside protection and potential upside—more safety than common stock but less claim than senior preferred, while still allowing extra gains if the company performs well, similar to having a reserved seat that also lets you join the crowd when there’s a bonus.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does APVO’s Rights Agreement expire?

The amended definition of Aptevo’s Final Expiration Date is October 23, 2027. Amendment No. 6 was entered into with Broadridge Corporate Issuer Solutions, LLC, as rights agent, on October 23, 2026.

What is the Purchase Price under APVO’s Rights Agreement?

The amended Purchase Price is $14.56 per one one-thousandth of a Preferred Share. The Preferred Share is Series A Junior Participating Preferred Stock with a par value of $0.001 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
false000167158400016715842026-10-232026-10-23

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2026

 

 

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37746

81-1567056

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2401 4th Avenue

Suite 1050

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

APVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 1.01 Entry into a Material Definitive Agreement.

On October 23, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 6 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (as amended and/or restated from time to time, the “Rights Agreement”). The Rights Agreement pertains to those certain contingent rights to purchase one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001, of the Company (each, a “Preferred Share”).

The Amendment extends the definition of “Final Expiration Date” (as defined in the Rights Agreement) and certain related language in the Rights Agreement to October 23, 2027. The Amendment also changes the definition of “Purchase Price” (as defined in the Rights Agreement) and certain related language in the Rights Agreement to $14.56 per one one-thousandth of a Preferred Share.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is attached as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 3.03 Material Modification to Rights of Security Holders.

 

The information set forth under “Item 1.01 Entry into a Material Definitive Agreement” of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Number

Description

4.1

Amendment No. 6 to Rights Agreement, dated as of October 23, 2026, between the Company and Broadridge Corporate Issuer Solutions, LLC, as Rights Agent

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

APTEVO THERAPEUTICS INC.

 

 

 

 

Date:

October 23, 2026

By:

/s/ Daphne Taylor

 

 

 

Daphne Taylor
Senior Vice President and Chief Financial Officer

 


Filing Exhibits & Attachments

2 documents

Keep reading